Improving apoptotic responses to targeted therapy
- PMID: 23934756
- PMCID: PMC3824529
- DOI: 10.18632/oncotarget.1261
Improving apoptotic responses to targeted therapy
Comment on
-
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4321-6. doi: 10.1073/pnas.1205575110. Epub 2013 Feb 27. Proc Natl Acad Sci U S A. 2013. PMID: 23447565 Free PMC article.
References
-
- Eifert C, Powers RS. Nat Rev Cancer. 2012;12:572–578. - PubMed
-
- Davies H, et al. Proc Natl Acad Sci U S A. 2013
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
